Overall Status

Recruiting (3)

Completed (1)

Terminated (1)

Phase

n/a (2)

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

AIO-Studien-gGmbH (1)

Centre Jean Perrin (1)

Centre Oscar Lambret (1)

ECS-Progastrin SA (1)

Hospices Civils de Lyon (1)

Collaborator

Anticancer Fund, Belgium (1)

Assign Data Management and Biostatistics GmbH (1)

Bristol-Myers Squibb (1)

CTD-CNO (1)

Centre Hospitalier Princesse Grace (1)

ECS Progastrin (1)

ECS-Progastrin SA (1)

Novartis Pharmaceuticals (1)

Intervention

blood draws (1)

blood sample (1)

capecitabine (1)

cyclophosphamide (1)

everolimus (afinitor®) (1)

nivolumab (1)

progastrin (1)

vinblastine (1)

Study Documents

Intervention Type

drug (2)

biological (1)

diagnostic test (1)

other (1)

Funder Type

Other (4)

Industry (1)

Study Type

Interventional (4)

Observational (1)

Progastrin

Showing 1 - 5 of 5

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

hPG80 asBlood Biomarker for High-grade Glial Tumors

Recruiting

Glial Cell Tumors

Blood sample

Clermont-Ferrand, France

Centre Jean PERRIN

Feb 14, 2022

Colon Cancer Screening, Healthy Person Trial in Montpellier (progastrin)

Terminated

Colon Cancer Screening
Healthy Person

progastrin

Montpellier, MC, France

Centre Hospitalier Princesse Grace, Monaco

Jan 12, 2022

Cancer, Breast Cancer, Gastric Cancer Trial in Bron, Lyon, Pierre-Bénite (Blood draws)

Recruiting

Cancer
+16 more

Blood draws

Bron, France
+16 more

Jul 12, 2021

Childhood Solid Tumor Trial in Belgium, France (Vinblastine, Cyclophosphamide, Capecitabine)

Recruiting

Childhood Solid Tumor

Vinblastine
+3 more

Brussel, Belgium
+10 more

May 27, 2022

Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3, Neuroendocrine Carcinoma, Grade 1

Completed

Poorly Differentiated Malignant Neuroendocrine Carcinoma
+4 more

Everolimus (Afinitor®)

Berlin, Germany

Charité-Universitätsmedizin, Medizinische Klinik m. S. Hepatolog

Oct 27, 2020